Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Axsome Therapeutics (AXSM) EBITDA Margin (2022 - 2026)

Axsome Therapeutics' EBITDA Margin history spans 5 years, with the latest figure at 33.14% for Q1 2026.

  • On a quarterly basis, EBITDA Margin rose 1378.0% to 33.14% in Q1 2026 year-over-year; TTM through Mar 2026 was 6.33%, a 7977.0% increase, with the full-year FY2025 number at 6.03%, up 6672.0% from a year prior.
  • EBITDA Margin hit 33.14% in Q1 2026 for Axsome Therapeutics, down from 51.7% in the prior quarter.
  • Over the last five years, EBITDA Margin for AXSM hit a ceiling of 51.7% in Q4 2025 and a floor of 14523.4% in Q4 2024.
  • Historically, EBITDA Margin has averaged 1010.94% across 5 years, with a median of 89.62% in 2024.
  • Biggest five-year swings in EBITDA Margin: tumbled -1438601bps in 2024 and later skyrocketed 1457510bps in 2025.
  • Tracing AXSM's EBITDA Margin over 5 years: stood at 245.86% in 2022, then surged by 44bps to 137.39% in 2023, then plummeted by -10471bps to 14523.4% in 2024, then skyrocketed by 100bps to 51.7% in 2025, then plummeted by -164bps to 33.14% in 2026.
  • Business Quant data shows EBITDA Margin for AXSM at 33.14% in Q1 2026, 51.7% in Q4 2025, and 26.97% in Q3 2025.